Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
COREGO: drug–drug interaction analysis on the efficacy and safety of regorafenib in patients with a sarcoma: pooled analysis of the data from the REGOSARC and REGOBONE trials
F Rethouze, Severine Risbourg, Camille Schiffler, Sylvie Chabaud, Antoine De Courreges, Marie‐Cécile Le Deley, Jean Yves Blay, Frédéric Feutry, Marta Jimenez, Marie Vanseymortier, Nicolas Penel, Florence Duffaud, Loïc Lebellec (2025). COREGO: drug–drug interaction analysis on the efficacy and safety of regorafenib in patients with a sarcoma: pooled analysis of the data from the REGOSARC and REGOBONE trials. , 10(6), DOI: https://doi.org/10.1016/j.esmoop.2025.105117.
Article18 days agoLBA98 Final results of the RAR-IMMUNE study: A randomized, comparative, prospective, multicenter phase III trial of the efficacy of nivolumab + ipilimumab (N+I) versus pazopanib (P) in patients (pt) with advanced sarcoma (S) of rare subtype
M. Brahmi, Camille Schiffler, M. Toulmonde, Thibaud Valentin, Agnès Ducoulombier, Christophe Perrin, N. Penel, Isabelle Desmoulins, C. Tlemsani, François Bertucci, Justine Gantzer, Nicolás Isambert, L. Chaigneau, Isabelle Laure Ray-Coquard, Séverine Metzger, David Pérol, Jean Yves Blay, A. Dufresne (2025). LBA98 Final results of the RAR-IMMUNE study: A randomized, comparative, prospective, multicenter phase III trial of the efficacy of nivolumab + ipilimumab (N+I) versus pazopanib (P) in patients (pt) with advanced sarcoma (S) of rare subtype. , 36, DOI: https://doi.org/10.1016/j.annonc.2025.09.115.
Article18 days agoVP3-2024: A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse
Axel Le Cesne, Camille Schiffler, Olivier Bouché, Mehdi Brahmi, F. Duffaud, Maud Toulmonde, B. Landi, W. Lahlou, Diane Pannier, Emmanuelle Bompas, François Bertucci, L. Chaigneau, Olivier Collard, Marc Pracht, Antoine Adenis, Isabelle Ray‐Coquard, Séverine Metzger, Sylvie Chabaud, David Pérol, Jean Yves Blay (2024). VP3-2024: A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse. , 35(6), DOI: https://doi.org/10.1016/j.annonc.2024.04.004.
Article18 days agoA randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse
Jean Yves Blay, Camille Schiffler, Olivier Bouché, Mehdi Brahmi, F. Duffaud, Maud Toulmonde, B. Landi, W. Lahlou, Diane Pannier, Emmanuelle Bompas, François Bertucci, L. Chaigneau, Olivier Collard, Marc Pracht, Clémence Hénon, I. Ray-Coquard, K Armoun, Sébastien Salas, Mariella Spalato Ceruso, Antoine Adenis, B. Verret, Nicolas Penel, Camille Moreau-Bachelard, A. Italiano, Armelle Dufresne, Séverine Metzger, Sylvie Chabaud, David Pérol, A. Le Cesne (2024). A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse. , 35(12), DOI: https://doi.org/10.1016/j.annonc.2024.08.2343.
Article18 days agoA randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse
Jean Yves Blay, Camille Schiffler, Olivier Bouché, Mehdi Brahmi, F. Duffaud, Maud Toulmonde, B. Landi, W. Lahlou, Diane Pannier, Emmanuelle Bompas, François Bertucci, L. Chaigneau, Olivier Collard, Marc Pracht, Clémence Hénon, I. Ray-Coquard, K Armoun, Sébastien Salas, Mariella Spalato Ceruso, Antoine Adenis, B. Verret, Nicolas Penel, Camille Moreau-Bachelard, A. Italiano, Armelle Dufresne, Séverine Metzger, Sylvie Chabaud, David Pérol, A. Le Cesne (2024). A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse. , 35(12), DOI: https://doi.org/10.1016/j.annonc.2024.08.2343.
Article18 days ago